BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36914943)

  • 1. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
    Kao WY; Tan EC; Lee HL; Huang YH; Huo TI; Chang CC; Chiou JF; Hou MC; Wu JC; Su CW
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1299-1312. PubMed ID: 36914943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
    J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
    Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
    Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
    Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
    Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.
    Giri S; Agrawal D; Afzalpurkar S; Gopan A; Angadi S; Sundaram S
    J Viral Hepat; 2023 Feb; 30(2):108-115. PubMed ID: 36321967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir versus tenofovir on the recurrence of hepatitis B-related HCC after liver transplantation: A multicenter observational study.
    Kim DG; Choi Y; Rhu J; Hwang S; You YK; Kim DS; Nah YW; Kim BW; Cho JY; Kang KJ; Yang JD; Choi D; Joo DJ; Kim MS; Ryu JH; Lee JG;
    Liver Transpl; 2023 Dec; 29(12):1272-1281. PubMed ID: 37489922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
    Linye H; Zijing X; Xiaoyun Z; Zhihui L; Tianfu W; Chuan L
    Int J Surg; 2023 Oct; 109(10):3032-3041. PubMed ID: 37335984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
    Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
    Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
    Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
    Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
    Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
    Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
    Peng W; Yi M; Qi X; Qi W; Li C; Wen T
    Trials; 2023 Dec; 24(1):781. PubMed ID: 38042834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.
    Tsai MC; Wang CC; Lee WC; Lin CC; Chang KC; Chen CH; Hung CH; Lin MT; Hsiao CC; Chen CL; Chien RN; Hu TH
    Liver Cancer; 2022 Jan; 11(1):22-37. PubMed ID: 35222505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
    Choi H; Seo GH
    J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
    Lin CL; Lin YL; Liang KH; Chen LW; Chien CH; Hu CC; Huang TS; Shyu YC; Yeh CT; Chien RN
    Clin Ther; 2022 Mar; 44(3):403-417.e6. PubMed ID: 35469645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.